Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

SPPI Spectrum Pharmaceuticals Inc

0.00 (0.00%)
Pre Market
Last Updated: 20:00:00
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 1.14
Ask Price 0.9785
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Spectrum Pharmaceuticals Inc SPPI NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.03 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.92685 - 1.1299
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.03 USD

Spectrum Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 211.42M - - - -7.94
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Spectrum Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No SPPI Message Board. Create One! See More Posts on SPPI Message Board See More Message Board Posts

Historical SPPI Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year1.051.12990.926850.9955351,161,789-0.02-1.90%
3 Years4.234.430.3151.273,020,866-3.20-75.65%
5 Years7.5010.570.3152.332,493,775-6.47-86.27%

Spectrum Pharmaceuticals Description

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor G-CSF for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer NSCLC tumors with various mutations.

Your Recent History

Delayed Upgrade Clock